Gout - Pipeline Review, Q1 2011

Date: February 1, 2011
Pages: 47
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: GB7AB06C11EEN
Leaflet:

Download PDF Leaflet

Gout - Pipeline Review, Q1 2011
Gout - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Gout - Pipeline Review, Q1 2011', provides an overview of the Gout therapeutic pipeline. This report provides information on the therapeutic development for Gout, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gout. 'Gout - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Gout.
  • A review of the Gout products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Gout pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Gout.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Gout pipeline depth and focus of Gout therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gout Overview
Therapeutics Development
An Overview of Pipeline Products for Gout
Gout Therapeutics under Development by Companies
Gout Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Gout Therapeutics Development
Novartis AG
Addex Pharmaceuticals
Ardea Biosciences, Inc.
BioCryst Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
XOMA Ltd.
Metabolex, Inc
Wellstat Therapeutics Corporation
PLx Pharma Inc.
EnzymeRx, Inc.
Allostera Pharma Inc.
Nuon Therapeutics, Inc.
Universities/Institutes Involved in Gout Therapeutics Development
Gout - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
ACZ885 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Arcalyst - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Zoledronate - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Discontinued Products
Gout - Featured News
1. DEC 22, 2010: BIOCRYST INITIATES PHASE IIB STUDY OF BCX4208 AS ADD-ON THERAPY IN GOUT PATIENTS NOT RESPONDING TO ALLOPURINOL ALONE
2. NOV 08, 2010: BIOCRYST TO PRESENT NEW DATA FOR BCX4208 MONOTHERAPY AT 74TH ANNUAL AMERICAN COLLEGE OF RHEUMATOLOGY SCIENTIFIC MEETING
3. SEP 29, 2010: NUON THERAPEUTICS TO PRESENT GOUT PROGRAM STUDY RESULTS AT AMERICAN COLLEGE OF RHEUMATOLOGY MEETING 2010
4. SEP 16, 2010: BIOCRYST REPORTS POSITIVE RESULTS FROM A PHASE II STUDY OF BCX4208 COMBINED WITH ALLOPURINOL IN PATIENTS WITH GOUT
5. SEP 16, 2010: BIOCRYST ANNOUNCES POSITIVE PHASE II STUDY RESULTS OF BCX4208 COMBINED WITH ALLOPURINOL IN PATIENTS WITH GOUT
6. JUN 18, 2010: NOVARTIS REPORTS NEW DATA FROM PHASE II STUDY OF ACZ885 IN GOUT PATIENTS
7. JUN 18, 2010: ARDEA PRESENTS POSITIVE PHASE II DATA ON RDEA594 FOR TREATMENT OF HYPERURICEMIA AND GOUT AT EULAR ANNUAL EUROPEAN CONGRESS
8. JUN 18, 2010: ARDEA PRESENTS INTERIM RESULTS FROM PHASE IB STUDY OF RDEA594 IN COMBINATION WITH ALLOPURINOL FOR TREATMENT OF HYPERURICEMIA AND GOUT AT EULAR ANNUAL EUROPEAN CONGRESS
9. JUN 18, 2010: ARDEA PRESENTS DATA FROM PROOF-OF-CONCEPT STUDY EXAMINING COMBINATION OF RDEA594 AND FEBUXOSTAT FOR TREATMENT OF HYPERURICEMIA AND GOUT AT EULAR ANNUAL EUROPEAN CONGRESS
10. JUN 09, 2010: ARCALYST (RILONACEPT) MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN PHASE 3 TRIAL OF PREVENTION OF GOUT FLARES IN PATIENTS INITIATING ALLOPURINOL THERAPY
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 47

LIST OF TABLES

Number of Products Under Development for Gout, 2011
Products under Development for Gout – Comparative Analysis, 2011
Comparative Analysis by Late Stage Development, 2011
Comparative Analysis by Mid Clinical Stage Development, 2011
Comparative Analysis by Early Clinical Stage Development, 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, 2011
Novartis AG, 2011
Addex Pharmaceuticals, 2011
Ardea Biosciences, Inc., 2011
BioCryst Pharmaceuticals, Inc., 2011
Regeneron Pharmaceuticals, Inc., 2011
XOMA Ltd., 2011
Metabolex, Inc, 2011
Wellstat Therapeutics Corporation, 2011
PLx Pharma Inc., 2011
EnzymeRx, Inc., 2011
Allostera Pharma Inc., 2011
Nuon Therapeutics, Inc., 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Discontinued Products 36

LIST OF FIGURES

Number of Products under Development for Gout, 2011
Products under Development for Gout – Comparative Analysis, 2011
Products under Development by Companies, 2011
Products under Investigation by Universities/Institutes, 2011
Late Stage Products, 2011
Mid Clinical Stage Products, 2011
Early Clinical Stage Products, 2011
Discovery and Pre-Clinical Stage Products, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011 31
Gouty Arthritis (Gout) - Pipeline Review, H2 2013 US$ 2,000.00 Aug, 2013 · 103 pages
Gout - Pipeline Review, Q4 2010 US$ 500.00 Dec, 2010 · 50 pages
3SBio Inc. – Product Pipeline Review – H2 2011 US$ 500.00 Oct, 2011 · 46 pages
Ipsen S.A. – Product Pipeline Review – H2 2011 US$ 500.00 Nov, 2011 · 172 pages

Ask Your Question

Gout - Pipeline Review, Q1 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: